raloxifene hydrochloride has been researched along with Angiogenesis, Pathologic in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cohen, PR | 1 |
| Alencar, AP; da Silva, BB; de Castro-Leão, AH; dos Santos, AR; Lopes-Costa, PV; Pires, CG | 1 |
| Dai, H; Wang, B; Zhang, J; Zhang, P; Zhao, S | 1 |
| Carolin, KA; Pass, HA | 1 |
1 review(s) available for raloxifene hydrochloride and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Prevention of breast cancer.
Topics: Adult; Aged; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Apoptosis; Biological Products; Breast Neoplasms; Breast Neoplasms, Male; Carotenoids; Cathepsin D; Cell Adhesion Molecules; Cell Cycle; Clinical Trials, Phase III as Topic; Drug Screening Assays, Antitumor; Estrogens, Non-Steroidal; Female; Fenretinide; Genetic Predisposition to Disease; Hormone Antagonists; Humans; Isoflavones; Male; Mammary Neoplasms, Experimental; Mastectomy; Mice; Middle Aged; Neovascularization, Pathologic; Ovariectomy; Phytoestrogens; Plant Preparations; Raloxifene Hydrochloride; Rats; Retinoids; Risk Assessment; Risk Factors; Selenium; Tamoxifen; Terpenes | 2000 |
3 other study(ies) available for raloxifene hydrochloride and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Melasma treatment: A novel approach using a topical agent that contains an anti-estrogen and a vascular endothelial growth factor inhibitor.
Topics: Administration, Topical; Anastrozole; Androstadienes; Aromatase Inhibitors; Estrogens; Female; Genetic Predisposition to Disease; Humans; Hyperpigmentation; Letrozole; Male; Melanosis; Neovascularization, Pathologic; Nitriles; Pregnancy; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles; Ultraviolet Rays; Vascular Endothelial Growth Factor A | 2017 |
Effects of raloxifene on Ki-67 and CD34 antigen expression in breast cancer.
Topics: Adult; Aged; Antigens, CD34; Biomarkers; Biopsy, Needle; Breast Neoplasms; Cohort Studies; Female; Follow-Up Studies; Humans; Immunohistochemistry; Ki-67 Antigen; Mastectomy, Segmental; Microvessels; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neovascularization, Pathologic; Observer Variation; Preoperative Care; Probability; Raloxifene Hydrochloride; Receptors, Estrogen; Reference Values; Risk Assessment; Sensitivity and Specificity; Survival Rate; Treatment Outcome | 2009 |
Regulation of the vascular endothelial growth factor and growth by estrogen and antiestrogens through Efp in Ishikawa endometrial carcinoma cells.
Topics: Blotting, Western; Cell Line, Tumor; Cell Proliferation; Endometrial Neoplasms; Enzyme-Linked Immunosorbent Assay; Estrogen Receptor Modulators; Estrogens; Female; Gene Expression; Humans; Neovascularization, Pathologic; Raloxifene Hydrochloride; Receptors, Estrogen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tamoxifen; Transcription Factors; Transfection; Tripartite Motif Proteins; Ubiquitin-Protein Ligases; Vascular Endothelial Growth Factor A | 2009 |